Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Apr 28, 2025 · CIK: 1860657
Sentiment: neutral
Topics: 8-k, financials, exhibits
Related Tickers: ALLR
TL;DR
ALLARITY THERAPEUTICS FILES 8-K, FINANCIALS AND EXHIBITS REPORTED.
AI Summary
Allarity Therapeutics, Inc. filed an 8-K on April 28, 2025, reporting events as of April 25, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates routine corporate reporting, likely related to financial statements and exhibits, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any significant new risks or material adverse events.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- April 25, 2025 (date) — Date of earliest event reported
- April 28, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of April 25, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Allarity Therapeutics, Inc.
In which state was Allarity Therapeutics, Inc. incorporated?
Allarity Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Allarity Therapeutics, Inc.?
The address of the principal executive offices is 123 E Tarpon Ave, Tarpon Springs, FL 34689.
What is the telephone number for Allarity Therapeutics, Inc.?
The registrant's telephone number, including area code, is (401) 426-4664.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 28, 2025 regarding Allarity Therapeutics, Inc. (ALLR).